Microbio appoints Colin Keating as CEO

Colin Keating

Brisbane, 24 October 2023 – Microbio Ltd, an Australian molecular pathogen diagnostics company, is pleased to announce the appointment of Colin Keating as CEO, effective from 1 November 2023. Mr Keating joined Microbio as interim COO in May and assumed the role of interim CEO in early June.

Mr Keating’s experience delivering transformation programs at companies including MindBio Therapeutics enabled him to develop a strategic vision, in collaboration with the Board, to achieve significant regulatory and clinical trial milestones. These activities will lay the foundation for progression into full commercialisation in 2024.

“Colin has delivered on the Board’s expectations, introducing a new level of rigour and structure necessary for Microbio as we progress towards commercialisation,” said Board Chair Mary Harney.

“Microbio’s execution capability has been significantly enhanced and the progress of our clinical trials and regulatory roadmap has been encouraging.”

Mr Keating has been appointed on a two-year contract from 1 November 2023.

“I am thrilled to join the team at Microbio,” said Mr Keating.

“I look forward to working with the high-performing team to bring the benefits of our flagship product, InfectID-Bloodstream Infection, to improve how clinicians manage sepsis.”

Mr Keating’s appointment reinforces Microbio’s commitment to driving commercial success, delivering value for shareholders and advancing healthcare through innovative in vitro diagnostics.